Numbers
Figures converted from INR at historical FX rates — see fx_rates.json for the rate table. Ratios, margins, and multiples are unitless and unchanged.
The Numbers: Edelweiss Financial Services
Edelweiss trades at a recovery multiple because it is still rehabilitating from a 2020 near-collapse. The holding company has halved its debt from peak, margins are rebuilding, and FY2026 PAT of $72.5M is the highest since FY2019. But the market assigns a conglomerate discount — the structure is complex, the cost of debt remains high (implied ~13%), and RBI restrictions on the asset reconstruction arm are a lingering overhang. The single metric that would most rerate this stock: two consecutive quarters of consolidated PAT above $2.1M, proving the asset-light/co-lending model is durably profitable. Below that run-rate, the recovery case is still aspirational.
Snapshot
Current Price
Market Cap
Revenue (FY2026)
ROE
P/E Ratio
Current price $1.20, market cap $1,151M. Revenue for FY2026 reached $1,110M — recovering toward the FY2019 peak of $1,186M. ROE at 13.5% is respectable but not exceptional for a financial services firm; P/E of 17.6x sits above its own 10-year median of approximately 13x but well below most Indian financial peers.
Is This a Well-Run Business That Will Still Be Around in 10 Years?
What this tells you in two sentences: Edelweiss has spent five years methodically repairing a balance sheet that nearly broke in FY2020. The deleveraging from 7.9x debt/equity to 4.1x is the strongest signal of management discipline, but interest coverage at 1.24x leaves minimal margin for error — the company is not out of the woods yet.
Revenue & Earnings Power — 12-Year View
FY2020 was a near-death experience: operating margin collapsed from 59% to 26% as wholesale loan impairments ripped through the P&L. Since then, revenue has recovered to within 6% of its all-time high, but operating margins remain structurally lower — 30% in FY2026 versus 59% in FY2019 — reflecting the deliberate shift away from capital-intensive wholesale lending toward lower-margin but safer co-lending and fee-based models.
Quarterly Direction
The Q3 FY2026 spike to $49.0M is an outlier — driven by a large one-time transaction in the alternatives business, not organic lift. Strip it out and the underlying quarterly run-rate is roughly $21–27M, consistent with a business that has stabilized but is not yet accelerating.
Cash Generation — Are the Earnings Real?
Cash conversion is the single biggest red flag on this file. For a non-lending financial, you want operating cash flow tracking net income. Instead, operating CF has been profoundly negative in expansion phases (FY2016–2018) and lumpy ever since. The FY2025 operating CF of $24.0M against net income of $6.3M (383% conversion) looks strong, but the 5-year average is distorted by the FY2020 distressed sale cycle. Trailing 5-year CFO/NI ratio is 574% — well over 120%, driven by balance sheet shrinkage and wholesale loan sell-downs, not sustainable earnings conversion. Watch for CFO to settle closer to 1.0–1.5x NI in a normalized year.
Capital Allocation
The company has prioritized debt repayment over shareholder returns, which is appropriate for a levered holding company in recovery. Dividends resumed modestly but there is no meaningful buyback history. The primary capital allocation story is the unwinding of the FY2018-era debt binge through asset sales (Nuvama stake, WestBridge AMC stake sale, Carlyle Nido Home Finance deal) and the pivot to co-lending — a capital-light model that shifts credit risk to banking partners. This is disciplined behavior, but it is forced discipline: Edelweiss does not have the balance sheet to grow aggressively on its own book.
Balance Sheet Health
Total borrowings have fallen from a peak of $751M (FY2018) to $198M (FY2026) — a 74% reduction in USD terms. But the FY2024 equity base also shrunk (reserves dropped due to a one-time goodwill write-down), which mechanically pushed debt/equity back up. The direction is right; the absolute level of 4.11x remains high for a holding company. Interest expense consumed $26.6M in FY2026 — 80% of operating income. That is a heavy burden that leaves little room for error if credit conditions tighten.
Valuation — Now vs Its Own History
Current P/E
5-Year Median P/E
Premium to 5Y Median
The stock currently trades at 19.8x trailing earnings — a 52% premium to its 5-year median of 13.0x, and nearly 2 standard deviations above its 20-year mean of approximately 12x. This is the highest P/E Edelweiss has commanded outside of the FY2018 euphoria peak (15.0x). The market is pricing in a successful deleveraging and business model transition that has not yet fully materialized in the P&L. Either earnings must accelerate meaningfully from here, or the multiple is vulnerable to compression.
Peer Comparison
Edelweiss sits in the middle of the peer pack on returns (ROE 13.5%, ROCE 14.1%) but trades at a significant P/E discount to MOTILALOFS, ANGELONE, and ANANDRATHI — all of which have cleaner business models and stronger growth trajectories. The discount is partly justified by Edelweiss's holding company complexity, higher leverage, and past governance concerns, but the gap versus IIFL (P/E 11.8x) and JMFINANCIL (10.5x) is narrower, suggesting the market groups Edelweiss with the "recovering NBFC/holding company" cohort rather than the high-growth wealth management names.
Fair Value & Scenario
There is no active analyst consensus for Edelweiss, and the company does not provide forward guidance. Using the available data:
- Bear case ($0.80–0.91): Earnings stall at $5.3–5.9M as the co-lending ramp disappoints and credit costs rise. Multiple compresses to 13–15x (5-year median). Implies a price of $0.80–0.91.
- Base case ($1.07–1.24): PAT grows to $7.5–8.0M in FY2027 as mutual fund and alternatives businesses compound. Multiple holds at 17–18x. Implies $1.07–1.24.
- Bull case ($1.49–1.65): PAT accelerates to $9.1–9.6M driven by successful ARC resolution and AMC listing catalyst. Multiple expands to 20–22x on structural re-rating. Implies $1.49–1.65.
At the current $1.20, the stock is priced slightly above the base case midpoint. A sustained quarterly PAT above $2.1M ($8.5M annual run-rate) is the threshold that would shift the probability weight from bear/base to base/bull.
The Bottom Line
What the numbers confirm: Edelweiss's deleveraging is real — debt has fallen 74% from its FY2018 peak in USD terms, and the pivot to asset-light models (co-lending, AMC, wealth) is showing in the margin structure. FY2026 net profit of $72.5M is the best since FY2019, and ROCE has improved for four consecutive years.
What the numbers contradict: The popular "turnaround" narrative overstates the pace of recovery. Operating margins have not recovered to pre-crisis levels (30% vs 59%), interest coverage at 1.24x remains fragile, and cash flow from operations has been too lumpy to use as a reliable compass. This is a stabilization, not a breakout.
What to watch next: Q1 and Q2 FY2027 quarterly PAT — two consecutive quarters above $2.1M would confirm the $8.5M annual run-rate, which would likely trigger a re-rating toward the bull case. Conversely, a quarterly miss below $1.6M would call the recovery thesis into question and compress the multiple back toward the 5-year median of 13x.